• Study participant must be 6 to \<18 years of age, inclusive, at the time of signing the informed consent/assent according to local regulation

• Study participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit

• Study participant meets the following at both the Screening and Baseline Visits:

‣ Body surface area (BSA) affected by PSO ≥10%

⁃ . Investigator's Global Assessment (IGA) score ≥3 (on a scale from 0 to 4)

⁃ . Psoriasis Area and Severity Index (PASI) score ≥12 OR

∙ PASI score ≥10 plus at least 1 of the following:

∙ i) Clinically relevant facial involvement ii) Clinically relevant genital involvement iii) Clinically relevant hand and foot involvement

• Study participant is a candidate for systemic PSO therapy and/or photo/chemotherapy and for treatment with ustekinumab per labeling

• Study participant has body weight ≥15 kg and body mass index for age percentile of ≥5 at Screening